Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 9
Submit an article Journal homepage
743
Views
9
CrossRef citations to date
0
Altmetric
Author's View

Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients

Karthick Raja Muthu Raja Babak Myeloma Group; Department of Pathological Physiology; Faculty of Medicine; Masaryk University; Brno, Czech RepublicCorrespondence[email protected]
&
Roman Hajek Babak Myeloma Group; Department of Pathological Physiology; Faculty of Medicine; Masaryk University; Brno, Czech Republic; Department of Clinical Hematology; University Hospital of Brno; Brno, Czech Republic; Department of Hemato-oncology; University Hospital of Ostrava; Ostrava, Czech Republic
Article: e25619 | Received 27 Jun 2013, Accepted 02 Jul 2013, Published online: 09 Jul 2013

References

  • Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3 - 9; http://dx.doi.org/10.1038/leu.2008.291; PMID: 18971951
  • Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012; 7:e47077; http://dx.doi.org/10.1371/journal.pone.0047077; PMID: 23071717
  • Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012; 7:e35981; http://dx.doi.org/10.1371/journal.pone.0035981; PMID: 22666318
  • Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2005; 2:11 - 9; PMID: 16212906
  • Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One 2012; 7:e49446; http://dx.doi.org/10.1371/journal.pone.0049446; PMID: 23152910
  • Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012; 53:1406 - 8; http://dx.doi.org/10.3109/10428194.2011.652106; PMID: 22200079
  • Muthu Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hájek R. Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry Part B: Clinical Cytometry 2013; Forthcoming http://dx.doi.org/10.1002/cytob.21109
  • Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10:155 - 67; http://dx.doi.org/10.2174/156800910791054239; PMID: 20088798
  • Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117:1605 - 13; http://dx.doi.org/10.1182/blood-2010-04-278432; PMID: 20978269

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.